Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.27), $0.07 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.87 million versus the consensus estimate of $9.28 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Jannik Sinner says he will not compete at US Open due to injury
• Apollo reports security breach affecting user personal data